Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

Conference’s opening session addresses the evolving landscape of healthcare coverage and accessibility.

Access USA 2024: The State of the Industry

This financial toxicity is quite prominent, but what can be done to remedy treatment costs?

Cancer’s Financial Burden Being Felt Worldwide

With out-of-pocket healthcare costs resulting in financial issues for patients, a cross-sectional study closely examines whether they are linked to more premature deaths.  

Is There a Correlation Between Medical Debt and Health Status?

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

US Government Considers Banning Dealings with WuXi AppTec, Affiliates

The contributions consist of multiple investments that aim to boost pandemic preparedness and overall public health protection. 

AstraZeneca Intends to Make $831 Million Financial Commitment in the UK

Momentum from the previous two years will propel the sector into the rest of 2024, says AM Best analysis.

Report: The Future of the Health Insurance Market Appears Stable

A Carrum Health/PWC report surveys benefit managers spanning various self-insured employers in an effort to determine ways to improve the cancer treatment experience, especially from a cost perspective. 

Finding the Ideal Set of Oncology Employer Benefits 

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

Identifying Trends Surrounding the Use of In-House Pharmacies for High-Cost Drugs

The annual report published by IQVIA examines movement surrounding drug launches and new clinical trials, during the post-pandemic era.

Investigating Trends in the Pharmaceutical Research & Development Space

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications. 

Business and Finance